FDA asks how early ibogaine trials should be run; comments close November 20

What is FDA asking for?

In a request for information published October 6, 2026 (91 FR 63563, Docket FDA-2026-N-10429), FDA describes the approaches it is considering for early-phase ibogaine trials and asks for comments, data and information on them.¹ The topics include dose selection and escalation, the care setting, safety monitoring, who can enroll, stopping rules and safety oversight.¹

FDA says it's asking in part because the federal government is now paying for this work. The Department of Health and Human Services is funding early-phase safety and efficacy trials through the Advanced Research Projects Agency for Health (ARPA-H), and ibogaine research for opioid use disorder through the National Institute on Drug Abuse.¹

FDA isn't asking about everything. The notice says it isn't seeking comments on ibogaine's scheduling status, on legalization or decriminalization, or on religious, ceremonial or personal use, and that comments on those topics may not be considered.¹ Regulations.gov showed 28 posted comments on the docket on November 2, 2026.²

What risks does FDA describe?

FDA says clinical data show ibogaine "commonly causes substantial QTc interval prolongation, which has been associated with life-threatening ventricular arrhythmias and death." In plain terms, it can disturb the heart's electrical rhythm.¹

The notice names three serious risks that the approaches it's considering are meant to address: QTc prolongation "and the associated risk of life-threatening arrhythmia," "neurotoxicity in nonclinical studies," and "uncertainty regarding an appropriate starting dose for humans."¹

What would an ibogaine trial look like?

FDA's working model is hospital care. The setting "should be an inpatient unit equipped to manage a life-threatening arrhythmia," likely with continuous heart rhythm monitoring, a physician-led team trained in advanced cardiac life support, a defibrillator at the bedside, emergency cardiac pacing and ventilator support.¹

Heart monitoring could last as long as 36 hours, and participants would stay in a monitored unit, for example at least 36 hours after dosing, until they meet discharge criteria.¹

Possible enrollees are adults 18 to 55 who have stopped psychiatric medications. Likely exclusions include structural cardiovascular disease, a personal or family history of arrhythmia or sudden cardiac death, a history of seizures, psychosis or bipolar disorder, recent suicidal thoughts, and pregnancy.¹

Dosing would pause for review if, among other triggers, a participant has a sustained ventricular arrhythmia or a seizure, QTc prolongation above 500 ms persists more than two days, or a death or serious adverse event possibly related to ibogaine occurs.¹

Has FDA looked at ibogaine before?

FDA's Drug Abuse Advisory Committee discussed an ibogaine application for cocaine dependence in 1993, and the notice says the questions raised then "remain relevant today." More recently, FDA allowed an early-phase study of noribogaine hydrochloride, a derivative of ibogaine, to proceed as a potential treatment for alcohol use disorder.¹

FDA ties the request to Executive Order 14401, signed April 18, 2026, which says "psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy."¹³

Why it matters in Miami

Ibogaine is a Schedule I drug in Florida, listed at 893.03(1)(c)18.⁴ No ibogaine study on ClinicalTrials.gov lists a Florida site.⁵

Ibogaine is given in treatment settings outside the United States, and FDA says its thinking drew partly on information about ibogaine given in those settings.¹ For anyone in South Florida weighing a trip abroad for it, the notice is the federal regulator's own description of the cardiac risk and of the hospital-level monitoring it thinks a trial needs. If someone faints, has a seizure or has an irregular heartbeat after taking any drug, call 911; our help page lists local resources.